{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:46:27Z","timestamp":1786988787714,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015831","name":"Radius Health Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015831","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.eprac.2024.10.017","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T21:14:43Z","timestamp":1731705283000},"page":"159-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50\u00a0Years of Age and Older: Update of a Real-World Retrospective Analysis"],"prefix":"10.1016","volume":"31","author":[{"given":"Laila","family":"Tabatabai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Cosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi T.","family":"DeSapri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton T.","family":"LaBaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Rizzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Cortet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Joseph","family":"Chiodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce H.","family":"Mitlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2024.10.017_bib1","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician's guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eprac.2024.10.017_bib2","first-page":"785","article-title":"NIH consensus development panel on osteoporosis prevention, diagnosis, and therapy. Osteoporosis prevention, diagnosis, and therapy","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.eprac.2024.10.017_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10192","article-title":"Healthcare policy changes in osteoporosis can improve outcomes and reduce costs in the United States","volume":"3","author":"Lewiecki","year":"2019","journal-title":"JBMR Plus"},{"key":"10.1016\/j.eprac.2024.10.017_bib4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mayocp.2014.09.011","article-title":"Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States","volume":"90","author":"Singer","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.eprac.2024.10.017_bib5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1080\/00325481.2022.2069582","article-title":"The role of osteoanabolic agents in the management of patients with osteoporosis","volume":"134","author":"McClung","year":"2022","journal-title":"Postgrad Med"},{"key":"10.1016\/j.eprac.2024.10.017_bib6","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/GME.0000000000001831","article-title":"Management of osteoporosis in postmenopausal women: the 2021 position statement of the North American Menopause Society","volume":"28","year":"2021","journal-title":"Menopause"},{"key":"10.1016\/j.eprac.2024.10.017_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American association of clinical endocrinologists\/American College of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2024.10.017_bib8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jbmr.3877","article-title":"Secondary fracture prevention: consensus clinical recommendations from a multistakeholder coalition","volume":"35","author":"Conley","year":"2020","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.eprac.2024.10.017_bib9","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society\u2217 clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2024.10.017_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","article-title":"Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures","volume":"31","author":"Kanis","year":"2020","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eprac.2024.10.017_bib11","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s00198-021-05942-2","article-title":"An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines: a report for the National Osteoporosis Guideline Group (NOGG)","volume":"32","author":"Kanis","year":"2021","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eprac.2024.10.017_bib12","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s00198-020-05541-7","article-title":"Core principles for fracture prevention: North American Consensus from the National Osteoporosis Foundation, Osteoporosis Canada, and Academia Nacional de Medicina de Mexico","volume":"31","author":"Lewiecki","year":"2020","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eprac.2024.10.017_bib13","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/OGX.0000000000001181","article-title":"Diagnosis and management of osteoporosis: a comprehensive review of guidelines","volume":"78","author":"Rentzeperi","year":"2023","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.eprac.2024.10.017_bib14","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update","volume":"105","author":"Shoback","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2024.10.017_bib15","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40520-022-02100-4","article-title":"Management of patients at very high risk of osteoporotic fractures through sequential treatments","volume":"34","author":"Curtis","year":"2022","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.eprac.2024.10.017_bib16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2024.10.017_bib17","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2024.10.017_bib18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling","volume":"157","author":"Hattersley","year":"2016","journal-title":"Endocrinology"},{"key":"10.1016\/j.eprac.2024.10.017_bib19","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.eprac.2024.10.017_bib20","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2024.10.017_bib21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00223-018-0422-4","article-title":"Abaloparatide exerts bone anabolic effects with less stimulation of bone resorption-related factors: a comparison with teriparatide","volume":"103","author":"Makino","year":"2018","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.eprac.2024.10.017_bib22","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00198-020-05806-1","article-title":"Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling","volume":"32","author":"Winzenrieth","year":"2021","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eprac.2024.10.017_bib24","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00198-023-06827-2","article-title":"Real-world evidence: new opportunities for osteoporosis research. Recommendations from a working group from the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO)","volume":"34","author":"Moon","year":"2023","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eprac.2024.10.017_bib25","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.eprac.2024.10.017_bib26","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s43441-024-00616-7","article-title":"Real-world evidence to support the registration of a new osteoporosis medicinal product in Europe","volume":"58","author":"Davenport","year":"2024","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.eprac.2024.10.017_bib27","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00198-022-06413-y","article-title":"Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: a US administrative claims database study","volume":"33","author":"Cosman","year":"2022","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eprac.2024.10.017_bib28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chronic Dis"},{"key":"10.1016\/j.eprac.2024.10.017_bib29","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"10.1016\/j.eprac.2024.10.017_bib30","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/jbmr.3807","article-title":"The design and validation of a new algorithm to identify incident fractures in administrative claims data","volume":"34","author":"Wright","year":"2019","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.eprac.2024.10.017_bib32","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1046\/j.1524-4733.2003.65261.x","article-title":"Methodology for estimating current and future burden of osteoporosis in state populations: application to Florida in 2000 through 2025","volume":"6","author":"Burge","year":"2003","journal-title":"Value Health"},{"key":"10.1016\/j.eprac.2024.10.017_bib33","first-page":"605","article-title":"Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations","volume":"14","author":"Tosteson","year":"2008","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.eprac.2024.10.017_bib34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s40520-023-02682-7","article-title":"Comparison of the cost-effectiveness of sequential treatment with abaloparatide in US men and women at very high risk of fractures","volume":"36","author":"Hiligsmann","year":"2024","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.eprac.2024.10.017_bib35","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40273-023-01270-x","article-title":"Cost-effectiveness of sequential abaloparatide\/alendronate in men at high risk of fractures in the United States","volume":"41","author":"Hiligsmann","year":"2023","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.eprac.2024.10.017_bib36","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.semarthrit.2019.01.006","article-title":"Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture","volume":"49","author":"Hiligsmann","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.eprac.2024.10.017_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2018.09.020","article-title":"Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis","volume":"120","author":"Diez-Perez","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.eprac.2024.10.017_bib38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00223-018-0485-2","article-title":"Reduction of hip and other fractures in patients receiving teriparatide in real-world clinical practice: integrated analysis of four prospective observational studies","volume":"104","author":"Silverman","year":"2019","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.eprac.2024.10.017_bib39","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","author":"Leder","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2024.10.017_bib40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jbmr.3003","article-title":"One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption","volume":"32","author":"Varela","year":"2017","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.eprac.2024.10.017_bib41","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1359\/jbmr.2001.16.1.157","article-title":"Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys","volume":"16","author":"Burr","year":"2001","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.eprac.2024.10.017_bib42","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00198-017-4323-6","article-title":"Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption","volume":"29","author":"Doyle","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eprac.2024.10.017_bib43","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00198-010-1226-1","article-title":"Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis","volume":"22","author":"Macdonald","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eprac.2024.10.017_bib44","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1359\/JBMR.040112","article-title":"Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity","volume":"19","author":"Sato","year":"2004","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.eprac.2024.10.017_bib45","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00198-018-4624-4","article-title":"Effects of osteoporosis drug treatments on cortical and trabecular bone in the femur using DXA-based 3D modeling","volume":"29","author":"Winzenrieth","year":"2018","journal-title":"Osteoporos Int"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24008279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24008279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T18:21:15Z","timestamp":1740594075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X24008279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1530891X24008279"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.10.017","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50\u00a0Years of Age and Older: Update of a Real-World Retrospective Analysis","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}